PAHC - フィブロ・アニマル・ヘルス (Phibro Animal Health Corporation) フィブロ・アニマル・ヘルス

 PAHCのチャート


 PAHCの企業情報

symbol PAHC
会社名 Phibro Animal Health Corp. (フィブロ・アニマル・ヘルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 フィブロ・アニマル・ヘルス(Phibro Animal Health Corporation)は世界的な多様化した動物健康とミネラル栄養会社である。同社は動物健康、ミネラル栄養と性能製品3つの事業を含む。同社は抗菌剤、抗コクシジウム剤、ワクチン、栄養補助食品及びミネラル栄養製品などの動物用健康製品を含む多様な製品を提供する。同社はまた、パーソナルケア、自動車、工業化学および化学触媒産業で使用するための特定の原料を製造・販売する。同社の医薬品飼料添加物(MFAs)及びその他の事業は、濃縮飼料製品で構成され、動物飼料で管理される。MFAとその他の事業は、Stafac、Terramycin、Neo-TerramycinおよびMecadoxを含む抗菌剤、並びにNicarb、Aviax、Aviax Plus、Coxistacおよびamproliumを含む抗コクシジウム剤の製造・販売からなる。   フィブロ・アニマル・ヘルスは米国で動物用医薬品と栄養剤を製造、販売。「スタファック」、「エスカリン」、「Vマックス」などのブランド名で家畜用の抗生物質、抗コクシジウム剤、ワクチン、栄養剤、ミネラル剤、特殊原料を提供。大規模農場が多い米国、ブラジル中国、ロシア、オ―ストラリア、カナダなどに販売のタ―ゲットに置く。   Phibro Animal Health Corp. engages in the manufacture of animal health and mineral nutrition products. It operates through the following business segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops, manufactures, and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment comprises of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment offers production of specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.
本社所在地 Glenpointe Centre East 3rd Floor 300 Frank W. Burr Boulevard Suite 21 Teaneck NJ 07666-6712 USA
代表者氏名 Jack Clifford Bendheim ジャッククリフォードベンドハイム
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 201-329-7300
設立年月日
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 1500人
url www.pahc.com
nasdaq_url https://www.nasdaq.com/symbol/pahc
adr_tso
EBITDA EBITDA(百万ドル) 125.82100
終値(lastsale) 42.89
時価総額(marketcap) 1732951921.52
時価総額 時価総額(百万ドル) 1782.927
売上高 売上高(百万ドル) 819.98200
企業価値(EV) 企業価値(EV)(百万ドル) 216.14
当期純利益 当期純利益(百万ドル) 67.57500
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Phibro Animal Health Corp revenues increased 7% to $820M. Net income before extraordinary items increased 5% to $67.6M. Revenues reflect Animal Health segment increase of 7% to $531.7M Mineral Nutrition segment increase of 8% to $234.9M Latin America and Canada segment increase of 25% to $120.9M Israel segment increase of 18% to $109.2M. Net income was partially offset by Selling.

 PAHCのテクニカル分析


 PAHCのニュース

   Animal Treatment Market (Impact of Covid-19) With Leading Players like Zoetis, Heska Corporation, Boehringer Ingelheim, Elanco, Ceva, Phibro Animal Health Corporation, Abaxis, Virbac SA, IDEXX Laboratories, Neogen Corporation  2020/11/09 14:12:15 OpenPR
The animal healthcare is a rapidly growing market which has full filled the needs of several livestock and companion animal species. Currently, various established companies are increasingly focusing on the development of healthcare products and services for companion animals. The
   Global Vaccine Adjuvants Market 2020-2027 Major Players Hitting the Reset Button || SPI Pharma, CSL Limited, Croda International Plc, Phibro Animal Health Corporation  2020/10/01 11:08:05 OpenPR
DBMR has added a new report titled Global Vaccine Adjuvants Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken
   Phibro Animal Health (PAHC) Q3 2020 Earnings Call Transcript | The Motley Fool  2020/05/09 15:30:44 The Motley Fool
PAHC earnings call for the period ending March 31, 2020.
   Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?  2020/04/15 15:50:12 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
   Article: Animal health share prices begin recovery during COVID-19 crisis  2020/04/02 06:08:29 IHS Markit
Read below an article taken from our Animal Health platform dated 30/03/20. The coronavirus outbreak was declared a pandemic by the WHO on March 11. Over the course of March, a range of animal health companies witnessed a fall in share value. Such firms included IDEXX Laboratories, Zoetis, Elanco, Phibro Animal Health, Covetrus and Virbac. IDEXX's share value previously endured one of the sharpest declines - falling 32% in value. From March 11 to March 20, the firm's stock fell from $245.58 to $183.29. However, the company's shares have begun to recuperate their value and is currently trading at approximately $232 each. Zoetis had also witnessed a significant decrease in its share price, falling from $130.24 on March 11 to $96.31 on March 18. Now, the firm's stock had climbed back up to around $111 per share. Elanco's share price has also undergone a steady recovery. The share valuation climbed from a low of $15.53 on March 18 - its lowest ever pricing - to just under $22. Elanco recently retracted its financial guidance for 2020 due to the pandemic and expects to deliver a new forecast later this year.
   Phibro Animal Health (PAHC) Q3 2020 Earnings Call Transcript | The Motley Fool  2020/05/09 15:30:44 The Motley Fool
PAHC earnings call for the period ending March 31, 2020.
   Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?  2020/04/15 15:50:12 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
   Article: Animal health share prices begin recovery during COVID-19 crisis  2020/04/02 06:08:29 IHS Markit
Read below an article taken from our Animal Health platform dated 30/03/20. The coronavirus outbreak was declared a pandemic by the WHO on March 11. Over the course of March, a range of animal health companies witnessed a fall in share value. Such firms included IDEXX Laboratories, Zoetis, Elanco, Phibro Animal Health, Covetrus and Virbac. IDEXX's share value previously endured one of the sharpest declines - falling 32% in value. From March 11 to March 20, the firm's stock fell from $245.58 to $183.29. However, the company's shares have begun to recuperate their value and is currently trading at approximately $232 each. Zoetis had also witnessed a significant decrease in its share price, falling from $130.24 on March 11 to $96.31 on March 18. Now, the firm's stock had climbed back up to around $111 per share. Elanco's share price has also undergone a steady recovery. The share valuation climbed from a low of $15.53 on March 18 - its lowest ever pricing - to just under $22. Elanco recently retracted its financial guidance for 2020 due to the pandemic and expects to deliver a new forecast later this year.
   Why Is Phibro (PAHC) Down 7.9% Since Last Earnings Report?  2020/03/04 16:30:24 Zacks Investment Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Phibro Animal Health Corporation Introduces OmniGen™ Pro  2020/02/18 18:32:00 Business Wire
TEANECK, N.J.--(BUSINESS WIRE)--Nutritional specialty product helps dairy cows be healthy and stay healthy. Phibro Animal Health Corporation introduces Omnigen Pro.
   Phibro Animal Health (PAHC) Q3 2020 Earnings Call Transcript | The Motley Fool  2020/05/09 15:30:44 The Motley Fool
PAHC earnings call for the period ending March 31, 2020.
   Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?  2020/04/15 15:50:12 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
   Article: Animal health share prices begin recovery during COVID-19 crisis  2020/04/02 06:08:29 IHS Markit
Read below an article taken from our Animal Health platform dated 30/03/20. The coronavirus outbreak was declared a pandemic by the WHO on March 11. Over the course of March, a range of animal health companies witnessed a fall in share value. Such firms included IDEXX Laboratories, Zoetis, Elanco, Phibro Animal Health, Covetrus and Virbac. IDEXX's share value previously endured one of the sharpest declines - falling 32% in value. From March 11 to March 20, the firm's stock fell from $245.58 to $183.29. However, the company's shares have begun to recuperate their value and is currently trading at approximately $232 each. Zoetis had also witnessed a significant decrease in its share price, falling from $130.24 on March 11 to $96.31 on March 18. Now, the firm's stock had climbed back up to around $111 per share. Elanco's share price has also undergone a steady recovery. The share valuation climbed from a low of $15.53 on March 18 - its lowest ever pricing - to just under $22. Elanco recently retracted its financial guidance for 2020 due to the pandemic and expects to deliver a new forecast later this year.
   Why Is Phibro (PAHC) Down 7.9% Since Last Earnings Report?  2020/03/04 16:30:24 Zacks Investment Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Phibro Animal Health Corporation Introduces OmniGen™ Pro  2020/02/18 18:32:00 Business Wire
TEANECK, N.J.--(BUSINESS WIRE)--Nutritional specialty product helps dairy cows be healthy and stay healthy. Phibro Animal Health Corporation introduces Omnigen Pro.

 関連キーワード  (医薬品 米国株 フィブロ・アニマル・ヘルス PAHC Phibro Animal Health Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)